🔎 Trials Near Me

Akèy › Gliyòm › Illinois

Etid klinik pou Gliyòm nan Illinois

13 etid pou Gliyòm ap chèche patisipan nan sit nan Illinois.

Vil nan Illinois

Tèks ofisyèl etid la (Anglè)

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  • University of Chicago Comprehensive Cancer Center, Chicago
  • OSF Children's Hospital of Illinois, Peoria
Ap rekriteFaz 1/2
12 Months – 21 Years · Tout sèks · Mizajou Oct 1, 2026 · NCT05099003

Targeted Pediatric High-Grade Glioma Therapy

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteEtid obsèvasyon
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Chicago, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 2
Laj 3 a 39 · Tout sèks · Mizajou Aug 24, 2026 · NCT05096481

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Aug 18, 2026 · NCT04485559

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  • Research Site, Chicago
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 12, 2026 · NCT05417594

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

  • Northwestern Medicine, Chicago
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07464925

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 1/2
Laj 1 a 26 · Tout sèks · Mizajou Jul 10, 2026 · NCT06712875

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 1 bonèVolontè an sante akeyi
Laj 1 a 21 · Tout sèks · Mizajou Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Northwestern Memorial Hospital, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT06810544

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

  • Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Ap rekriteFaz 1
12 Months – 18 Years · Tout sèks · Mizajou Mar 17, 2026 · NCT04943848

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.